Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

BACKGROUND: In this single-arm study, the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy were evaluated in patients with resectable esophageal squamous cell carcinoma (ESCC). METHODS: This study included patients with ESCC of clinical stages II–IVA who underwent surgery within 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Hongtao, Shao, Changjian, Pan, Minghong, Liu, Honggang, Dong, Xiaoping, Zhang, Yong, Tong, Liping, Feng, Yingtong, Wang, Yuanyuan, Wang, Lu, Newman, Neil B., Sarkaria, Inderpal S., Reynolds, John V., De Cobelli, Francesco, Ma, Zhiqiang, Jiang, Tao, Yan, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202755/
https://www.ncbi.nlm.nih.gov/pubmed/35720388
http://dx.doi.org/10.3389/fimmu.2022.849984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202755/
https://www.ncbi.nlm.nih.gov/pubmed/35720388
http://dx.doi.org/10.3389/fimmu.2022.849984

Ejemplares similares